Company Dossier · Health Care
Zoetis
- S&P 500
- Russell 1000
What Zoetis is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $9.53 billion, up 1.6% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $2.32 billion, up 2.2% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.52 billion, down 27% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $3.24 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $1.85 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 6, 2026): sentiment -0.60 on a −1 to +1 scale (negative), confidence 0.40 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 4 lowered, 1 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 12, 2026): 4 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q2 2026: $0.9 million on the open market.SEC Form 4
- 1,437 institutional managers reported a position at June 30, 2026 (−182 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 31 (56 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Zoetis is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Retrenching · Hedging
Expanding ↔ Retrenching
Retrenching
- Capital spending5th pct
- Debt raised—
- Buybacks vs capex8th pct
- Hiring filings22nd pct
- Deals and private raises49th pct
- Patent publications10th pct
Confident ↔ Hedging
Hedging
- Call sentiment2nd pct
- Call confidence3rd pct
- Guidance changes4th pct
- Risk factors added15th pct
- Insider open-market trades95th pct
- − Call sentiment
- − Guidance changes
- − Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver33rd pct
- Stress filings48th pct
Credit
How these are built →Zoetis's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$9.0B
- Due within a year $0.0B
- Longer term $9.0B
- Default point $4.5B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Aug 11, 2025 | $850M | 4.150% | 2028 (3y) | +45bp | 4.179% |
| Aug 11, 2025 | $1B | 5.000% | 2035 (10y) | +75bp | 5.023% |
From the pricing term sheets Zoetis filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Zoetis: earnings call confidence
Palanor Discourse score per call, 0 to 1
Hiring and ownership
In the news
Headlines that name Zoetis, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralZoetis' Simparica Trio Shows Superior Heartworm Protection; ZTS Dividend Remains Attractive
gurufocus.com · via Marketaux · Oct 6, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (ZOETIS INC.)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (WILLIAMS AND JENSEN, PLLC)third_quarter 2026 · $0.1 million
- Oct 14, 2026LobbyingLobbying report (THE RUSSELL GROUP, INC.)third_quarter 2026 · $0.1 million
- Oct 13, 20268-KDirector or officer changeItem 5.02
- Oct 13, 2026PatentPatent granted: FELINE ANTIBODY VARIANTSUS 12760107
- Sep 8, 2026Patent
- Aug 11, 2026Patent
- Aug 6, 20268-KDirector or officer changeItem 5.02
- Jul 20, 2026LobbyingLobbying report (ZOETIS INC.)second_quarter 2026 · $0.3 million
- Jul 20, 2026LobbyingLobbying report (WILLIAMS AND JENSEN, PLLC)second_quarter 2026 · $0.1 million
- Jul 16, 2026LobbyingLobbying report (THE RUSSELL GROUP, INC.)second_quarter 2026 · $0.1 million
- Jun 30, 2026Patent
- May 22, 20268-KDirector or officer changeItem 5.02
- May 22, 20268-KShareholder vote resultsItem 5.07
- May 12, 2026Patent
- Apr 20, 2026LobbyingLobbying report (ZOETIS INC.)first_quarter 2026 · $0.2 million
- Apr 20, 2026LobbyingLobbying report (WILLIAMS AND JENSEN, PLLC)first_quarter 2026 · $0.1 million
- Feb 12, 202610-KAnnual report (10-K)4 risk factors added, 0 removed
- Dec 18, 20258-KMaterial agreement signedItem 1.01
- Oct 28, 20258-KDirector or officer changeItem 5.02
- Aug 27, 20258-KMaterial agreement signedItem 1.01
- Aug 27, 20258-KMaterial agreement terminatedItem 1.02
- May 22, 20258-KDirector or officer changeItem 5.02
- May 22, 20258-KShareholder vote resultsItem 5.07
- Feb 13, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Dec 30, 2024Risk event
- Nov 12, 20248-KChange in controlItem 5.01
- Feb 13, 202410-KAnnual report (10-K)0 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Viatris VTRS | $14.7B | $1.9B | Jun 30, 2026 |
| Organon & Co. OGN | $6.1B | $0.6B | Jun 30, 2026 |
| Jazz Pharmaceuticals JAZZ | $4.6B | $1.6B | Jun 30, 2026 |
| Bristol Myers Squibb BMY | $49.2B | $11.4B | Jun 30, 2026 |
| Corcept Therapeutics CORT | $0.8B | $0.1B | Jun 30, 2026 |
| Biogen BIIB | $9.9B | $2.4B | Mar 31, 2026 |
| Zimmer Biomet ZBH | $8.5B | $1.5B | Jun 30, 2026 |
| Solventum SOLV | $8.3B | −$0.1B | Jun 30, 2026 |